TABLE OF CONTENTS
I EXECUTIVE SUMMARY
- A. Overview of Market Dynamics
- B. Prozac and Generic Fluoxetine
- C. Prilosec and Generic Omeprazole
- D. Mevacor and Generic Lovastatin
- E. Glucophage and Generic Metformin
- F. Taxol and Generic Paclitaxel
- G. Market Outlook for Generic Competition
- H. References
II BRANDS VS. GENERICS: CURRENT MARKET DYNAMICS
- A. Competition from Generics On the Rise
- B. Pressure for Cost Savings
- C. Role of Regulation
- D. References
III PROZAC AND GENERIC FLUOXETINE
- A. Pre-Generic Launch SSRI Market Dynamics
- 1. Sales
- 2. Prescriptions
- 3. Pricing
- 4. Brands' Line Extensions
- 5. Generic Manufacturers
B. Post-Generic Launch SSRI Market Dynamics
- 1. Sales
- 2. Prescription
- 3. Pricing
- 4. Brands' Promotional Support
- 5. Brands' Line Extensions and Portfolio Management
- 6. Expanding Sales Force
- 7. Investment in Online Detailing Efforts
- 8. New Product Launches
- C. SSRI Market Dynamics Overview: Quantitative Impact of Generics on Prozac and Other Brand SSRIs
- 1. Total Prescriptions
- 2. New Prescriptions
- 3. Generic Substitution Rate
- 4. Sales
- D. References
IV PRILOSEC AND GENERIC OMEPRAZOLE
- A. Pre-Generic Launch PPI Market Dynamics
- 1. Sales
- 2. Prescriptions
- 3. Pricing
- 4. Brands Promotional Support
- 5. Brands' Line Extensions
- 6. Generic Manufacturers
- B. Post-Generic Launch PPI Market Dynamics
- 1. Sales
- 2. Prescriptions
- 3. Pricing
- 4. Line Extension and Portfolio Management
- C. PPI Market Dynamics Overview: Quantitative Impact of Generics on Prilosec and Other Brand PPIs
- 1. Total Prescriptions
- 2. New Prescriptions
- 3. Generic Substitution Rate
- 4. Sales
- D. References
V MEVACOR AND GENERIC LOVASTATIN
- A. Pre-Generic Launch Statin Market Dynamics
- 1. Sales
- 2. Prescriptions
- 3. Pricing
- 4. Brands' Promotional Support
- 5. Brands' Line Extensions
- 6. Generic Manufacturers
- B. Post-Generic Launch Statin Market Dynamics
- 1. Sales
- 2. Prescriptions
- 3. Pricing
- 4. Brands' Line Extensions, Additional Indications, and Portfolio Management
- 5. Expanding Sales Force
- 6. New Product Launches
- C. Statin Market Dynamics Overview: Quantitative Impact of Generics on Mevacor and Other Brand Statins
- 1. Total Prescriptions
- 2. New Prescriptions
- 3. Generic Substitution Rate
- 4. Brand Sales
- D. References
VI GLUCOPHAGE AND GENERIC METFORMIN
- A. Pre-Generic Launch Biguanide Market Dynamics
- 1. Sales
- 2. Prescriptions
- 3. Pricing
- 4. Brands' Promotional Support
- 5. Brands' Line Extensions
- 6. Generic Manufacturers
- B. Post-Generic Launch Biguanide Market Dynamics
- 1. Sales
- 2. Prescriptions
- 3. Pricing
- 4. Line Extensions
- 5. Additional Dynamics
- C. Biguanide Market Dynamics Overview: Quantitative Impact of Generics on Glucophage
- 1. Total Prescriptions
- 2. New Prescriptions
- 3. Generic Substitution Rate
- 4. Sales
- D. References
VII TAXOL AND GENERIC PACLITAXEL
- A. Pre-Generic Launch Taxane Market Dynamics
- 1. Sales
- 2. Brands' Line Extensions
- 3. Pricing
- 4. Generic Manufacturers
- B. Post-Generic Launch Taxane Market Dynamics
- 1. Sales
- 2. Pricing
- C. Taxane Market Dynamics Overview: Quantitative Impact of Generics on Taxol and Other Branded Taxanes
- D. References
VIII MARKET OUTLOOK FOR GENERIC COMPETITION
- A. Upcoming Patent Expirations
- 1. Paxil (GlaxoSmithKline) and the SSRI Market
- 2. Nolvadex (AstraZeneca) and the Chemotherapy Market
- B. Biogenerics: A Looming Threat to Biotech Brands
- 1. Intron A (Schering-Plough) and the Hepatits B and C Market
- 2. Rebetol (Schering-Plough) and the Hepatitis C Market
- C. References
PARTIAL LIST OF TABLES AND FIGURES
Generics' Share of U.S. Prescription Drug Market, 1984-2000
Average Retail Prescription Price, 1990-2000
Market Launch of Generic Versions of Major Brands
Brand Launches within the SSRI Market
AWP-Based Cost per Day for Leading Brand SSRIs, 2001
Brand Product Line Extensions and New Chemical Entities in the SSRI Market
AWP-Based Cost Per Day for Leading SSRIs, 2001-2002
SSRIs and Impact of Generic Prozac: Total Prescription Market
SSRIs and Impact of Generic Prozac: Total Branded vs Generic Prozac Prescriptions
SSRIs and Impact of Generic Prozac: New Prescriptions Market
SSRIs and Impact of Generic Prozac: New Branded vs Generic Prozac Prescriptions
SSRIs and Impact of Generic Prozac: Dispensed New Prescriptions and Substitution Rate
Brand Launches within the PPI Market
AWP-Based Cost per Day for Leading Brand PPIs, 2001
AWP-Based Cost Per Day for Leading PPIs, 2002
PPIs and Impact of Generic Prilosec: Total Prescription Market
PPIs and Impact of Generic Prilosec: Total Branded vs Generic Prilosec Prescriptions
PPIs and Impact of Generic Prilosec: New Prescriptions Market
PPIs and Impact of Generic Prilosec: New Branded vs Generic Prilosec Prescriptions
PPIs and Impact of Generic Prilosec: Dispensed New Prescriptions and Substitution Rate
Brand Launches within the Statin Market
AWP-Based Cost per Day for Leading Brand Statins, 2001
AWP-Based Cost Per Day for Leading Statins, 2001-2002
Statins and Impact of Generic Mevacor: Total Prescription Market
Statins and Impact of Generic Mevacor: Total Branded vs Generic Mevacor Prescriptions
Statins and Impact of Generic Mevacor: New Prescriptions Market
Statins and Impact of Generic Mevacor: New Branded vs Generic Mevacor Prescriptions
Statins and Impact of Generic Mevacor: Dispensed New Prescriptions and Substitution Rate
Brand Launches within the Biguanides Market
AWP-Based Cost per Day for Leading Brand Biguanides, 2001
AWP-Based Cost Per Day for Leading Biguanides, 2002
Biguanides and Impact of Generic Glucophage: Total Prescription Market
Biguanides and Impact of Generic Glucophage: Total Branded vs Generic Glucophage Prescriptions
Biguanides and Impact of Generic Glucophage: New Prescriptions Market
Biguanides and Impact of Generic Glucophage: New Branded vs Generic Glucophage Prescriptions
Biguanides and Impact of Generic Glucophage: Dispensed New Prescriptions and Substitution Rate
Launches of Branded Taxanes
AWP-Based Cost of Therapy per Cycle, 2001
Average Cost of Therapy per Cycle (AWP) in 2001 and 2002
Taxane Sales and Impact of Generic Taxol
View Cart
